 There are different subtypes of DLBCL which are distinguished by their Cell of Origin ABC, GCB, unclassifiable. About a third of DLBCL is of the ABC subtype and as those patients have a worse outcome when treated with R-CHOP, lenalidomide plus R-CHOP R2-CHOP will be used for patients with the ABC subtype. 